1-2 of 2
Peter Borchmann, PD, Dr.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Matthias Haenel, Peter Borchmann, PD, Dr., Andreas Viardot, Christina Nickenig, Martin Bentz, MD, Christian Peschel, MD, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Bertram Glass, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 404.
https://doi.org/10.1182/blood.V114.22.404.404
Published: 2009
Journal Articles

Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10. Study Supported by the Deutsche Krebshilfe and in Part by the Competence Network Malignant Lymphoma.

Andreas Engert, MD, Volker Diehl, MD, Emeritus, Annette Pluetschow, Hans T. Eich, Richard Herrmann, MD, Bernd Doerken, Lothar Kanz, MD, Richard Greil, Jana Markova, Michael Fuchs, Peter Borchmann, PD, Dr., Hans Konrad Mueller-Hermelink, Rolf Peter Mueller
Journal: Blood
Blood (2009) 114 (22): 716.
https://doi.org/10.1182/blood.V114.22.716.716
Published: 2009